Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8306
|
| pubmed:dateCreated |
1982-12-16
|
| pubmed:abstractText |
Between 1978 and 1980 133 patients with acute myelogenous leukaemia were given allogeneic bone-marrow transplants from an HLA-identical sibling and were followed up for at least a year. Pre-transplant preparation consisted of high-dose chemotherapy and/or radiation and post-transplant immune suppression consisted of methotrexate or cyclosporin-A. Data for 76 patients transplanted in first transplanted in either second to fourth remission, partial remission, or relapse. The 2-year actuarial survival-rate was 48% (95% CI, 36-60%) for patients transplanted in first remission and 30% 95% CI, 17-43%) for patients with more advanced disease (p = 0.037). Disease status at the time of transplantation was related to the probability of survival (p less than 0.02). The 2-year actuarial leukaemia recurrence-rate was 32% for patients transplanted in first remission and 50% for patients with more advanced disease (p = 0.0017). The probability of remaining in remission also was associated with disease status at time of transplantation (p less than 0.01). The incidence of graft-vs-host disease and interstitial pneumonitis was similar for patients transplanted in first remission and those transplanted later, and methotrexate and cyclosporin A were equally effective in modifying acute GVHD. These data indicate that prolonged survival can be achieved in approximately one-half of patients with acute myelogenous leukaemia given transplants of bone marrow from an HLA-identical sibling during their first complete remission.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0140-6736
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
6
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1006-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:6127500-Adolescent,
pubmed-meshheading:6127500-Adult,
pubmed-meshheading:6127500-Antineoplastic Agents,
pubmed-meshheading:6127500-Bone Marrow Transplantation,
pubmed-meshheading:6127500-Child,
pubmed-meshheading:6127500-Child, Preschool,
pubmed-meshheading:6127500-Chronic Disease,
pubmed-meshheading:6127500-Female,
pubmed-meshheading:6127500-Follow-Up Studies,
pubmed-meshheading:6127500-Graft vs Host Reaction,
pubmed-meshheading:6127500-Humans,
pubmed-meshheading:6127500-Immunosuppressive Agents,
pubmed-meshheading:6127500-Infant,
pubmed-meshheading:6127500-Leukemia, Myeloid, Acute,
pubmed-meshheading:6127500-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:6127500-Male,
pubmed-meshheading:6127500-Middle Aged,
pubmed-meshheading:6127500-Postoperative Care,
pubmed-meshheading:6127500-Preoperative Care,
pubmed-meshheading:6127500-Pulmonary Fibrosis,
pubmed-meshheading:6127500-Recurrence
|
| pubmed:year |
1982
|
| pubmed:articleTitle |
Bone-marrow transplantation for acute leukaemia in first remission.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|